Lactobacillus acidophilus Deepsea100 with functions of reducing blood sugar, reducing fat and resisting aging and application of lactobacillus acidophilus Deepsea100

Abstract

The invention relates to the technical field of microorganisms, in particular to lactobacillus acidophilus Deepsea100 with functions of reducing blood sugar, reducing fat and resisting aging and application of the lactobacillus acidophilus Deepsea100. The lactobacillus acidophilus Deepsea100 is separated from the intestinal tract of New Zealand longevity fish, and the preservation number is CGMCC No.36868. The scavenging rate of a fermented product to DPPH free radicals is larger than or equal to 96%, the scavenging rate to hydroxyl free radicals is larger than or equal to 83%, the inhibition rates to alpha-amylase, alpha-glucosidase and pancreatic lipase are larger than or equal to 71%, larger than or equal to 65% and larger than or equal to 66% respectively, and the lactobacillus acidophilus Deepsea100 has the effects of resisting oxidation, reducing blood sugar and fat and resisting aging, and can be used for preparing a feed additive. And the feed is strong in gastric acid intestinal juice resistance and intestinal colonization capacity, free of hemolytic reaction, sensitive to antibiotics and high in food safety. The invention also provides a microbial agent, a probiotic product, a fermentation product and the like containing the strain, can be applied to food, health care products, cosmetics or animal feeds, has the functions of prolonging the service life, enhancing the reproductive capacity and the like, and is remarkable in application value.

Description

Technical Field

[0001] This invention relates to the field of microbial technology, and in particular to a Lactobacillus acidophilus Deepsea100 with functions of lowering blood sugar, reducing fat and anti-aging, and its applications. Background Technology

[0002] With the continuous transformation of the global population structure, aging has become an irreversible trend. The proportion of the global population aged 60 and above continues to increase, and the health challenges and social pressures brought about by aging have become core issues of global concern. The elderly often face physiological changes such as increased oxidative stress, metabolic dysfunction, and gut microbiota imbalance, which can lead to various chronic diseases such as diabetes, obesity, and cardiovascular disease. This not only seriously affects the quality of life of the elderly but also places a heavy burden on the healthcare system and social elderly care resources. Against this backdrop, developing safe, natural, and effective probiotic products to slow aging and improve the health of the elderly has become an important research direction urgently needing to be addressed in the fields of biomedicine and food science, with significant social value and application prospects.

[0003] Caenorhabditis elegans, with its short lifespan, small size, high reproduction rate, ease of culture, and high homology with the human genome, is an important model organism for anti-aging research. Currently, numerous studies have used the Caenorhabditis elegans model to screen and verify the anti-aging activities of various plant-derived polysaccharides. These polysaccharides are derived from natural plants such as wolfberry, tremella, astragalus, and kelp, and their mechanisms of action often involve scavenging reactive oxygen species and regulating the expression of aging-related genes, providing important theoretical basis for the development of probiotic products.

[0004] However, compared to the research fervor surrounding plant-derived active ingredients, research on anti-aging related microbial sources, especially lactic acid bacteria strains, remains underdeveloped. Lactic acid bacteria, as beneficial symbiotic bacteria in the human gut, are recognized as GRAS-level microorganisms, and their roles in regulating gut microbiota balance, improving digestion and absorption, and enhancing immunity have been widely confirmed. However, currently reported lactic acid bacteria strains mostly focus on exploring single functions, and some strains lack tolerance to the low pH environment of gastric juice and the effects of pepsin, bile salts in intestinal juice, and pancreatic enzymes, making it difficult for them to stably colonize the gut and exert a lasting probiotic effect. These problems significantly limit the development and application of lactic acid bacteria-derived anti-aging probiotic products.

[0005] Therefore, screening and developing a lactic acid bacteria strain that possesses multiple physiological activities such as blood sugar reduction, fat reduction, and anti-aging, while also exhibiting good tolerance to gastric and intestinal fluids, to fill the research gap in multifunctional anti-aging probiotic strains derived from microorganisms, remains a pressing technical problem to be solved in the field. Summary of the Invention

[0006] To obtain a lactic acid bacteria strain with multiple physiological activities including blood sugar reduction, fat reduction, and anti-aging, and with good tolerance to gastric and intestinal fluids, this invention provides a *Lactobacillus acidophilus* Deepsea100 with blood sugar reduction, fat reduction, and anti-aging functions, whose Latin scientific name is... Lactobacillus acidophilus The accession number is CGMCC No.36868. It was deposited on December 1, 2025, at the China General Microbiological Culture Collection Center, located at No.3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing.

[0007] Lactobacillus acidophilus Deepsea100 was isolated from the intestinal samples of New Zealand long-lived fish. Its fermentation products showed a DPPH free radical scavenging rate of ≥96%, a hydroxyl free radical scavenging rate of ≥83%, an α-amylase inhibition rate of ≥71%, an α-glucosidase inhibition rate of ≥65%, and a pancreatic lipase inhibition rate of ≥66%. The strain is resistant to gastric acid and bile salts, has good intestinal colonization ability, is sensitive to antibiotics, does not have a hemolytic reaction, and has high food safety.

[0008] The present invention also provides a microbial agent, the components of which include Lactobacillus acidophilus Deepsea100 as described above.

[0009] The present invention also provides a probiotic product, the components of which include Lactobacillus acidophilus Deepsea100 as described above.

[0010] The present invention also provides a fermentation product, the components of which include Lactobacillus acidophilus Deepsea100 as described above.

[0011] This invention also provides the application of Lactobacillus acidophilus Deepsea100 as described above in the preparation of food, health products, cosmetics, or animal feed; the food, health products, cosmetics, or animal feed have at least one of the following functions: (1) Extend lifespan; (2) Enhance reproductive capacity; (3) Improve heat stress resistance; (4) Enhance physical activity.

[0012] Compared with the prior art, the present invention has the following beneficial effects: The *Lactobacillus acidophilus* Deepsea100 provided by this invention possesses multiple core functions, including potent antioxidant activity, blood sugar reduction, fat reduction, and anti-aging. Its fermented products exhibit a DPPH free radical scavenging rate of ≥96% and a hydroxyl free radical scavenging rate of ≥83%, effectively resisting oxidative stress. It also shows inhibition rates of ≥71%, ≥65%, and ≥66% against α-amylase, α-glucosidase, and pancreatic lipase, respectively, regulating glucose and lipid metabolism at its source. Validated using *Caenorhabditis elegans* as a model, it can extend the average lifespan of nematodes by 13.48%, significantly enhancing reproductive capacity, heat stress tolerance, and motility.

[0013] In vitro simulated digestion experiments verified that the *Lactobacillus acidophilus* Deepsea100 achieved a survival rate of (95.70±0.49)% in simulated gastric fluid and (95.76±0.83)% in simulated intestinal fluid (bile salt concentration 0.2%), successfully crossing the digestive tract barrier. Simultaneously, its cell surface hydrophobicity reached 79.86%, and its adhesion to human colon cancer cells HT-29 reached (98.63±1.78) CFU / cell, significantly superior to existing strains, enabling stable colonization in the intestine and sustained probiotic effects.

[0014] Furthermore, the Lactobacillus acidophilus Deepsea100 is isolated from the intestines of New Zealand long-lived fish, and is a natural deep-sea strain. Hemolytic assays have confirmed that it does not cause hemolysis, is sensitive to antibiotics such as tetracycline and azithromycin, does not carry drug resistance genes, and has high food safety. It can be prepared into various dosage forms such as powder and capsules, and can also be used as a core ingredient in functional foods, health products, cosmetics, and animal feed. It is suitable for improving age-related health problems in the elderly and can also meet the needs of the general population for sugar and lipid management and anti-aging. Attached Figure Description

[0015] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0016] Figure 1 This is a colony morphology diagram of Lactobacillus acidophilus Deepsea100 in Example 1 of the present invention; Figure 2 This is a Gram staining image of Lactobacillus acidophilus Deepsea100 in Example 1 of the present invention; Figure 3 This is a graph showing the experimental data analysis of the DPPH free radical scavenging rate determination in Example 2 of the present invention; Figure 4 This is a graph showing the experimental data analysis of the hydroxyl radical scavenging rate determination in Example 2 of the present invention; Figure 5 This is a graph showing the experimental data analysis of the α-amylase inhibition rate determination in Example 3 of the present invention; Figure 6 This is a graph showing the experimental data analysis of the α-glucosidase inhibition rate determination in Example 4 of the present invention; Figure 7 This is a graph showing the experimental data analysis of pancreatic lipase inhibition rate determination in Example 5 of the present invention; Figure 8This is a lifespan survival curve of *Caenorhabditis elegans* in Example 6 of the present invention; Figure 9 This is an antibiotic susceptibility graph of Lactobacillus acidophilus Deepsea100 in Example 9 of the present invention; Figure 10 The hemolytic activity of Lactobacillus acidophilus Deepsea100 in Example 10 of this invention is shown in the figure. Figure 11 This is a hemolytic diagram of Staphylococcus aureus ATCC25923 in the positive control group of Example 10 of the present invention. Detailed Implementation

[0017] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments, and the technical features designed in the different embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0018] This invention provides a strain of Lactobacillus acidophilus Deepsea100 with functions of lowering blood sugar, reducing fat, and anti-aging. Its Latin scientific name is... Lactobacillus acidophilus The accession number is CGMCC No.36868. It was deposited on December 1, 2025, at the China General Microbiological Culture Collection Center, located at No.3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing.

[0019] Strain origin: The Lactobacillus acidophilus Deepsea100 was isolated from the intestinal sample of New Zealand long-lived fish. The DNA genome of the strain was extracted and amplified by PCR. The PCR amplification product was sequenced for 16S rRNA. By Blast sequence comparison, the 16S rRNA gene sequence of the strain was found to be highly homologous to Lactobacillus acidophilus, and it was named Lactobacillus acidophilus Deepsea100.

[0020] Colony morphology: On MRS solid medium, it is round, milky white and opaque, with a smooth, raised surface and neat edges.

[0021] Physiological and biochemical characteristics of the strain: A single colony of the Lactobacillus acidophilus Deepsea100 was picked for Gram staining and physiological and biochemical tests. The strain is Gram-positive, with thin rod-shaped cells, negative for catalase, and does not form spores.

[0022] Physiological and biochemical functions of the strain: The Lactobacillus acidophilus Deepsea100 is a natural strain from the deep sea, with high food safety, no hemolysis, and sensitivity to multiple antibiotics; it has strong in vitro antioxidant capacity and can effectively scavenge DPPH free radicals and hydroxyl free radicals; it can significantly inhibit the activity of α-amylase, α-glucosidase, and pancreatic lipase, and has hypoglycemic and lipid-reducing effects; it has anti-aging effects, can prolong the lifespan of Caenorhabditis elegans, enhance its reproductive capacity, improve heat stress tolerance and motility; it is resistant to gastric acid and bile salts, and has outstanding intestinal adhesion and colonization ability.

[0023] Strain Isolation Process: Take 5g of New Zealand long-lived fish intestinal sample, place it in a sterile homogenizing bag, add 45mL of 0.85% physiological saline, and mix thoroughly to obtain a sample solution; perform a 10-fold serial dilution of 100μL of the above sample solution, and take 100μL of each dilution factor. 3 10 4 10 5 100 μL of each sample was spread onto MRS solid medium plates containing 2.5% CaCO3 and incubated upside down at 37°C for 48 h. Colonies with good growth and large calcium dissolution zones were picked from the culture plates and repeatedly isolated and purified by streak plate isolation until single colonies were obtained. The isolated strain was named Deepsea100 and stored in a bacterial bank at -80°C using glycerol tubes. The MRS solid medium formula is as follows: 20.0g glucose, 15.0g agar powder, 10.0g tryptone, 10.0g beef extract, 5.0g yeast extract, 5.0g anhydrous sodium acetate, 2.0g dipotassium hydrogen phosphate, 2.0g ammonium citrate, 0.5g magnesium sulfate, 0.25g manganese sulfate monohydrate, 1.0mL Tween-80, 1L deionized water, pH=6.5 (removing 15.0g agar powder results in the MRS liquid medium).

[0024] Example 1 Identification of strain Deepsea100 1.1 Colony morphology identification The Deepsea100 glycerol-preserved strain was taken from the bacterial bank and inoculated into MRS liquid medium at an inoculation rate of 2% (v / v) for strain activation. The strain was cultured at 37°C for 24 h, and then streaked on MRS solid medium plates and incubated upside down at 37°C for 24 h to obtain single colonies.

[0025] Colony morphology reference Figure 1 As shown, the single colonies of the strain Deepsea100 are round, milky white and opaque, with a smooth, raised surface and neat edges.

[0026] 1.2 Physiological and Biochemical Experiments Single colonies exhibiting good growth were selected for Gram staining, and their physiological and biochemical parameters were measured. The experimental results were compared with those in Bergey's Manual of Systematic Bacteriology, 8th Edition, for preliminary identification of the bacterial species. Specifically, the Gram staining microscopic examination of strain Deepsea100 was as follows: Figure 2 As shown, Gram staining is purple, indicating a positive result; the cells are rod-shaped; catalase is negative; and no spores are formed.

[0027] 1.3 Identification of 16S rRNA (1) Extraction of strain DNA Take 2 mL of the bacterial culture medium into a centrifuge tube, centrifuge at 12000 rpm for 1 min, remove the supernatant, and retain the bacterial cells; Add 200 μL of 20 mg / mL lysozyme to a centrifuge tube and treat at 37°C for at least 30 min. Add 200 μL of solution A to a centrifuge tube, shake thoroughly or repeatedly pipette to suspend the cells, add 20 μL of 10 mg / mL RNase A to the suspension, mix thoroughly by inverting, and incubate at room temperature for 15 min to 30 min. Add 20 μL of 10 mg / mL proteinase K to a centrifuge tube, mix thoroughly, and digest at 55°C for 30 min to 60 min. During digestion, the centrifuge tube can be inverted several times to mix until the sample is completely digested and a clear, viscous bacterial solution is obtained. Add 200 μL of solution B to a centrifuge tube and mix thoroughly by inverting. If a white precipitate appears during this process, place it at 75°C for 15 to 30 minutes. The precipitate will disappear, and you can continue the operation. Add 200 μL of anhydrous ethanol to a centrifuge tube and mix thoroughly. During this process, flocculent precipitate may appear, which will not affect the extraction of strain DNA. Add the solution and flocculent precipitate to the adsorption column and let stand for 2 min. Centrifuge at 12000 rpm for 2 min, discard the waste liquid, and place the adsorption column into the collection tube; Add 600 μL of washing solution to the adsorption column, centrifuge at 12000 rpm for 1 min, discard the waste liquid, and place the adsorption column into the collection tube; Add 600 μL of washing solution to the adsorption column again, centrifuge at 12000 rpm for 1 min, discard the waste liquid, and put the adsorption column into the collection tube. Centrifuge at 12000 rpm for 2 min, then leave the adsorption column open at room temperature for 15 min to remove any residual washing solution from the adsorption column, so as to avoid the residual washing solution affecting subsequent enzyme digestion, PCR and other experimental operations. Place the adsorption column into a clean centrifuge tube, add 100 μL of preheated elution solution (preheated in a 65°C water bath) to the center of the adsorption membrane, let it stand at room temperature for 5 min, and centrifuge at 12000 rpm for 1 min. The elution buffer obtained by centrifugation was resuspended and added to the adsorption column. After being placed at room temperature for 2 minutes, it was centrifuged at 12,000 rpm for 2 minutes to obtain high-quality bacterial DNA.

[0028] The kit is a bacterial genomic DNA extraction kit sold by Tiangen Biotech (Beijing) Co., Ltd. Lysozyme buffer: 20 mmol / L Tris (pH=8.0), 2 mmol / L Na2-EDTA, 1.2% Triton X-100.

[0029] (2) PCR amplification of the 16S rRNA gene using strain DNA as a template. The DNA of the strain was amplified by PCR, and the PCR amplification product was then sequenced using 16S rRNA. The amplification primers used were the universal primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (5'-TACGGCTACCTTGTTACGACTT-3'). The PCR reaction system consisted of: 1 μL DNA, 2 μL 27F, 2 μL 1492R, 12.5 μL Premix Ex Taq, and 9.5 μL ddH2O. The PCR reaction conditions were: 94℃ pre-denaturation for 3 min; 94℃ denaturation for 30 s, 55℃ annealing for 30 s, 72℃ extension for 1 min, 30 cycles; 72℃ extension for 5 min.

[0030] The 16S rRNA sequencing company is Fuzhou Qingke Biotechnology Co., Ltd.

[0031] The sequencing results were searched for similar sequences in the NCBI database using the Blast software. The sequenced MPs-68 strain was compared with the 16S rRNA gene sequences of related species obtained from the gene bank. The gene sequences are as follows: 27F: 5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO. 1); 1492R: 5'-TACGGCTACCTTGTTACGACTT-3' (SEQ ID NO. 2); 16S rRNA gene sequence determination results:

[0032] Based on a comprehensive analysis of the colony morphology, cell morphology, physiological and biochemical characteristics, and 16S rRNA gene sequence of strain Deepsea100, and referring to Bergey's Manual of Systematic Bacteriology, 8th Edition, strain Deepsea100 was identified as *Lactobacillus acidophilus*. Lactobacillus acidophilus ).

[0033] Example 2: Determination of the antioxidant capacity of Lactobacillus acidophilus Deepsea100 After activating Lactobacillus acidophilus Deepsea100 stored in glycerol tubes for two generations, it was inoculated into MRS liquid medium at an inoculum of 2% (v / v) and cultured at 37°C for 24 h. The fermentation broth was then centrifuged at 4°C and 6000 rpm for 10 min, and the supernatant was retained for later use. At the same time, the fermentation broth of the strain was inactivated at 121°C for 15 min to prepare the inactivated fermentation broth, i.e., the post-generic, for later use.

[0034] 2.1 Determination of DPPH free radical scavenging rate Mix 500 μL of sample solution with 500 μL of 100 μmol / L DPPH solution, react at 25 °C in the dark for 30 min, then centrifuge the mixture at 9000 rpm for 10 min. Collect the supernatant and measure the absorbance at 517 nm using a UV-Vis spectrophotometer. The blank sample group used an equal volume of anhydrous ethanol instead of DPPH, and the control group used an equal volume of distilled water instead of the sample solution.

[0035] The calculation was performed according to the DPPH free radical scavenging rate formula [1]:

[0036] In formula [1], A: absorbance value of the experimental group at 517 nm; B: Absorbance value of the blank sample group at 517nm; C: Absorbance value of the control group at 517nm.

[0037] Figure 3 The graph shows the DPPH free radical scavenging rate data of various liquids. The results show that the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and its post-biotic have the best inhibition rate of DPPH free radical scavenging activity. The DPPH free radical scavenging rate of Lactobacillus acidophilus Deepsea100 fermentation supernatant is (96.28±0.15)%, and the DPPH free radical scavenging rate of Lactobacillus acidophilus Deepsea100 post-biotic is (97.14±0.34)%.

[0038] 2.2 Hydroxyl radical scavenging activity The hydroxyl radical scavenging capacity was determined using a Fenton reaction system. 1 mL of 0.435 mmol / L Brilliant Green, 2 mL of 0.5 mmol / L ferrous sulfate, and 1.5 mL of 3.0% (w / v) hydrogen peroxide were incubated in a water bath at 37°C for 30 min. The fermentation broth of the test strain was then centrifuged at 9000 rpm for 10 min. The supernatant was added to the above mixture, and the absorbance at 525 nm was measured. The control group used an equal volume of distilled water instead of the test strain supernatant, and the blank group contained only 0.435 mmol / L Brilliant Green. Each group was tested in triplicate.

[0039] The calculation was performed according to the hydroxyl radical scavenging rate formula [2]:

[0040] In formula [2], A: absorbance value of the experimental group at 525 nm; B: Absorbance value of the blank group at 525nm; C: Absorbance value of the control group at 525nm.

[0041] Figure 4 The graph shows the hydroxyl radical scavenging rate data of various liquids. The results show that the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and its post-biotic showed the best inhibition rate of hydroxyl radical scavenging activity. The hydroxyl radical scavenging rate of Lactobacillus acidophilus Deepsea100 fermentation supernatant was (86.59±0.23)%, and the hydroxyl radical scavenging rate of Lactobacillus acidophilus Deepsea100 post-biotic was (83.72±0.17)%.

[0042] Example 3: Determination of the inhibitory effect of Lactobacillus acidophilus Deepsea100 on α-amylase After activating Lactobacillus acidophilus Deepsea100 stored in glycerol tubes for 2-3 generations, it was inoculated into MRS liquid medium at an inoculum of 3% (v / v) and cultured at 37°C for 24 h. The fermentation broth was then centrifuged at 4°C and 6000 rpm for 10 min, and the supernatant was retained for later use. At the same time, the fermentation broth of the strain was inactivated at 121°C for 15 min to prepare the inactivated fermentation broth, i.e., the post-generic, for later use.

[0043] 125 μL of sample solution was mixed with an equal volume of 1 mg / mL α-amylase solution and incubated at 37 °C for 10 min. The mixture was then added to 250 μL of 1.5% soluble starch solution and reacted at 37 °C for 15 min. Next, 500 μL of DNS solution was added, and the mixture was reacted in a boiling water bath for 5 min, then rapidly cooled to room temperature. After dilution 20-fold, the mixture was allowed to stand for 30 min, and the absorbance was measured at 540 nm. The blank control group used an equal volume of PBS solution (0.1 mol / L, pH=6.8) instead of the α-amylase solution, and the control group used an equal volume of PBS solution instead of the sample solution. The blank control group contained only PBS solution. Each group was replicated in triplicate.

[0044] The calculation was performed according to the α-amylase inhibition rate formula [3]:

[0045] In formula [3], A: absorbance value of the experimental group at 540 nm; B: Absorbance value of the blank sample group at 540nm; C: Absorbance value of the control group at 540nm; D: Absorbance value of the blank group at 540nm.

[0046] Figure 5 The graph shows the data analysis of the inhibition rate of α-amylase by various liquids. The results showed that the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and the metabiotic had the highest inhibition rate of α-amylase. Among them, the inhibition rate of α-amylase by Lactobacillus acidophilus Deepsea100 fermentation supernatant was (71.73±1.26)%, and the inhibition rate of α-amylase by Lactobacillus acidophilus Deepsea100 metabiotic was (81.29±0.47)%.

[0047] Example 4: Determination of the inhibitory effect of Lactobacillus acidophilus Deepsea100 on α-glucosidase After activating Lactobacillus acidophilus Deepsea100 stored in glycerol tubes for 2-3 generations, it was inoculated into MRS liquid medium at an inoculum of 3% (v / v) and cultured at 37°C for 24 h. The fermentation broth was then centrifuged at 4°C and 6000 rpm for 10 min, and the supernatant was retained for later use. At the same time, the fermentation broth of the strain was inactivated at 121°C for 15 min to prepare the inactivated fermentation broth, i.e., the post-generic, for later use.

[0048] 50 μL of sample solution was mixed with 50 μL of 0.5 U / mL α-glucosidase solution and 50 μL of 0.2 mol / L sodium dihydrogen phosphate buffer (pH 6.8), and incubated at 37 °C for 15 min. Then, 100 μL of 4 mmol / L PNPG substrate was added, and the mixture was incubated at 37 °C for 20 min. Finally, 100 μL of 0.1 mol / L Na₂CO₃ was added to terminate the reaction, and the absorbance was measured at 405 nm. The sample blank group used an equal volume of ultrapure water instead of α-glucosidase, the control group used an equal volume of ultrapure water instead of sample solution, and the blank group used an equal volume of ultrapure water instead of both α-glucosidase solution and sample solution; each group was replicated in triplicate.

[0049] The calculation was performed according to the α-glucosidase inhibition rate formula [4]:

[0050] In formula [4], A: absorbance value of the experimental group at 405 nm; B: Absorbance value of the blank sample group at 405nm; C: Absorbance value of the control group at 405nm; D: Absorbance value of the blank group at 405nm.

[0051] Figure 6 The graph shows the data analysis of the inhibition rate of α-glucosidase by various samples. The results showed that the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and the post-biotic had the highest inhibition rate of α-glucosidase. The inhibition rate of α-glucosidase by Lactobacillus acidophilus Deepsea100 fermentation supernatant was (65.73±0.38)%, and the inhibition rate of α-glucosidase by Lactobacillus acidophilus Deepsea100 post-biotic was (72.43±0.29)%.

[0052] Example 5: Determination of the inhibitory effect of Lactobacillus acidophilus Deepsea100 on pancreatic lipase After activating Lactobacillus acidophilus Deepsea100 stored in glycerol tubes for 2-3 generations, it was inoculated into MRS liquid medium at an inoculum of 3% (v / v) and cultured at 37°C for 24 h. The fermentation broth was then centrifuged at 4°C and 6000 rpm for 10 min, and the supernatant was retained for later use. At the same time, the fermentation broth of the strain was inactivated at 121°C for 15 min to prepare the inactivated fermentation broth, i.e., the post-generic, for later use.

[0053] 200 μL of sample solution was mixed with an equal volume of 2 U / mL pancreatic lipase solution and incubated at 37 °C for 15 min. Immediately afterwards, 400 μL of 10 mmol / L pNPP solution was added and mixed thoroughly, then incubated at 37 °C for 15 min. After incubation, the mixture was quickly placed in a 100 °C water bath for 5 min to terminate the reaction. The mixture was then centrifuged at 6000 rpm for 5 min, and the supernatant was collected. The absorbance was measured at 405 nm. The sample blank group used an equal volume of ultrapure water instead of pancreatic lipase solution, the control group used an equal volume of ultrapure water instead of sample solution, and the blank group used an equal volume of ultrapure water instead of both pancreatic lipase solution and sample solution. Each group was replicated in triplicate.

[0054] The calculation was performed according to the α-pancreatic lipase inhibition rate formula [5]:

[0055] In formula [5], A: absorbance value of the experimental group at 405 nm; B: Absorbance value of the blank sample group at 405nm; C: Absorbance value of the control group at 405nm; D: Absorbance value of the blank group at 405nm.

[0056] Figure 7 The graph shows the data analysis of the inhibition rate of pancreatic lipase by various liquids. The results showed that the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and the post-biotic had the highest inhibition rate of pancreatic lipase. Among them, the inhibition rate of pancreatic lipase by Lactobacillus acidophilus Deepsea100 fermentation supernatant was (78.42±0.27)%, and the inhibition rate of pancreatic lipase by Lactobacillus acidophilus Deepsea100 post-biotic was (66.85±0.31)%.

[0057] Example 6: Anti-aging assay of Caenorhabditis elegans strain (1) Culture and synchronization treatment of Caenorhabditis elegans The nematode *C. elegans* was cultured using nematode growth medium (NGM). The nematodes were fed with *E. coli* OP50. After spreading the medium, the nematodes were cultured in a constant temperature and humidity incubator at 20°C. The nematodes were activated for 48 hours and then grew to the L4 stage, serving as a synchronization treatment model.

[0058] Lysis and synchronization: L4-stage nematodes were rinsed into sterile EP tubes with M9 buffer solution and the mixture was blown and washed until 1 mL of nematode solution remained. Sterile water, 0.5 M NaOH, and 30% H2O2 were mixed at a volume ratio of 1:2:6 to prepare a lysis buffer. 1 mL of the lysis buffer was placed in an EP tube and shaken until lysis was complete. The tube was then centrifuged at 3000 rpm for 1 min. The supernatant was discarded. The tube was rinsed twice with M9 solution and centrifuged again. The supernatant was discarded. The eggs at the bottom of the EP tube were aspirated with a pipette and dropped onto the cultured NGM medium. The medium containing the eggs was placed in a 20°C incubator. After about 48 h of synchronization, the nematodes grew to the L4 stage. These synchronized nematodes were used for subsequent experiments.

[0059] (2) Experimental grouping and nematode culture The samples were diluted with Escherichia coli OP50 bacterial suspension to final concentrations of 10, 100, and 100 times. 100 μL of the sample solution at different concentrations was taken and fed to Caenorhabditis elegans on NGM plates. The growth of nematodes under different concentrations was measured, and the optimal concentration was screened through survival rate experiments.

[0060] The normal group (NC group) consisted of 100 μL of Escherichia coli OP50 bacterial suspension, the experimental group consisted of Escherichia coli OP50 bacterial suspension containing Lactobacillus acidophilus Deepsea100 and its post-genetic agents, Lactobacillus rhamnosus C13 and its post-genetic agents, and Lactobacillus gasseri HN2-2 and its post-genetic agents, respectively, and the positive control group consisted of Escherichia coli OP50 bacterial suspension containing 1 mg / mL vitamin E.

[0061] (3) Screening of effective concentration After Caenorhabditis elegans was cultured to the L4 stage, it was synchronized. The eggs were then spread on NGM culture plates with different final concentrations of sample solution and cultured for 24 hours. The survival of the nematodes in each group was observed by counting the nematodes on the culture plates.

[0062] The experiment showed that when each experimental strain and its postbiotic were diluted 10 times, the survival rate of *C. elegans* was >90%. Therefore, subsequent experiments were determined to use a 10-fold dilution of each experimental strain and its postbiotic as the optimal effective and safe concentration.

[0063] (4) Life test Thirty L4-stage adults, synchronized after initialization, were transferred to new plates coated with samples of different concentrations, with two replicates per group. The egg stage was defined as day 0 of the nematode's lifespan. During the nematode breeding season, the nematodes were transferred to new NGM plates daily, and then every two days thereafter. To prevent nematode hatching from affecting the lifespan results, the nematodes were grown on NGM medium supplemented with 2.5% 5-FUdR. The mortality, loss, and survival of nematodes were recorded daily until all individuals died. A nematode was considered dead if it did not respond to a light touch of a platinum wire to its head and tail. Nematodes that hatched from within the body, escaped from the medium, or burrowed into the agar were removed.

[0064] The experimental data on the effects of each sample on the lifespan of *C. elegans* are recorded in Table 1; the experimental data on the effects of each sample on the growth and reproduction of *C. elegans* are recorded in Table 2; and the analysis results of the effects of each sample on the lifespan of *C. elegans* are recorded in Table 3.

[0065] Table 1. Record of the number of surviving individuals in the experiment on the effect of Caenorhabditis elegans lifespan.

[0066] Table 2. Record of the number of surviving individuals in the experiment affected by the growth and reproduction of *Caenorhabditis elegans*.

[0067] Table 3. Results of experimental data analysis on the effects of *Caenorhabditis elegans* lifespan.

[0068] From Tables 1 to 3 and Figure 8 It can be seen that the anti-aging effect of *Lactobacillus acidophilus* Deepsea100 fermentation supernatant and *C. elegans* treated with post-biotics was the best. The average lifespan of *C. elegans* treated with *Lactobacillus acidophilus* Deepsea100 fermentation supernatant was 19.13 days, an increase of 7.49%, and the average lifespan of *C. elegans* treated with *Lactobacillus acidophilus* Deepsea100 post-biotics was 20.20 days, an increase of 13.48%, both of which were much higher than those of the NC group and close to those of the VE-positive control group.

[0069] (5) Determination of reproductive capacity Reproductive capacity was assessed primarily by evaluating the effect of probiotics on the number of nematode progeny, thereby determining whether they would inhibit the progeny of *C. elegans*. Two L4-stage nematodes were selected from each group and placed on NGM medium containing the sample, two nematodes per plate, three plates per group. Nematodes were transferred to new plates every 24 hours, continuing for five days until oviposition was complete. Plates containing eggs were incubated at 20°C for 48 hours until hatching to the L4 stage, after which the eggs were counted. The total number of nematodes on each group's culture dish represented the oviposition rate, thus evaluating the reproductive capacity of *C. elegans*.

[0070] Table 4. Experimental Data Recording Table on the Influence of Oviposition on Caenorhabditis elegans var. elegans

[0071] As shown in Table 4, the fermentation supernatant of Lactobacillus acidophilus Deepsea100 and the post-biotic treatment of C. elegans showed the best oviposition effect. The oviposition of C. elegans treated with Lactobacillus acidophilus Deepsea100 reached 22 on day 5, and the oviposition of C. elegans treated with Lactobacillus acidophilus Deepsea100 post-biotic treatment was also 18 on day 5. Both were higher than the NC group and close to or even greater than the VE positive control group.

[0072] (6) Stress resistance experiment Synchronized L4 stage nematodes were randomly selected and placed into each treatment group, 30 nematodes / plate. After culturing at 20℃ for 5 days, the nematodes were transferred to a 37℃ incubator for 3 hours. The number of surviving nematodes was observed and recorded for 16 hours thereafter until no nematodes survived in the plate, and the survival status of each group was calculated.

[0073] Table 5. Data on surviving individuals of *Caenorhabditis elegans* during heat stress experiments.

[0074] As shown in Table 5, the survival rate of *C. elegans* treated with *Lactobacillus acidophilus* Deepsea100 fermentation supernatant and subsequent biogenic agent was the highest after 3 hours of heat stress at 37°C. The survival rate of *C. elegans* treated with *Lactobacillus acidophilus* Deepsea100 fermentation supernatant after 3 hours of heat stress at 37°C was 56.67%, and the survival rate of *C. elegans* treated with *Lactobacillus acidophilus* Deepsea100 post-biogenic agent after 3 hours of heat stress at 37°C was 65%, both higher than the NC group and close to the VE-positive control group.

[0075] (7) Vitality assessment After 7 days of synchronizing L4 stage nematodes into each treatment group, the viability of the nematodes was assessed by swallowing frequency and head wiggling.

[0076] Swallowing frequency: Six nematodes were randomly selected from each plate and their pharyngeal contractions were observed under a microscope. The number of swallowings was recorded within one minute of each nematode being tracked, and the average value was calculated.

[0077] Table 6. Data on the number of swallowings of Caenorhabditis elegans

[0078] As shown in Table 6, the supernatant of Lactobacillus acidophilus Deepsea100 fermentation and the Caenorhabditis elegans treated with postbiotics had the highest number of pharyngeal pump aspirations per minute. Specifically, the number of pharyngeal pump aspirations per minute for Caenorhabditis elegans treated with Lactobacillus acidophilus Deepsea100 fermentation supernatant was 111.83, and the number of pharyngeal pump aspirations per minute for Caenorhabditis elegans treated with Lactobacillus acidophilus Deepsea100 postbiotics was 117.83, both higher than the NC group and close to the VE positive control group.

[0079] Head swaying: Six L4 stage nematodes were selected from each group and their head swaying was observed under a microscope. The number of head swayings in 1 minute was observed on days 3, 7 and 11, and the average value was calculated to evaluate the nematode's motility.

[0080] Table 7. Head swaying data of Caenorhabditis elegans

[0081] As shown in Table 7, the *C. elegans* induced by *Lactobacillus acidophilus* Deepsea100 fermentation supernatant and post-biotic treatment exhibited the highest number of head movements per minute on days 7 and 11. Specifically, on day 7, the number of head movements per minute for *C. elegans* induced by *Lactobacillus acidophilus* Deepsea100 fermentation supernatant was 60.8 times, while that for *C. elegans* induced by post-biotic treatment was 63.3 times. On day 11, the number of head movements per minute for *C. elegans* induced by *Lactobacillus acidophilus* Deepsea100 fermentation supernatant was 32.2 times, while that for *C. elegans* induced by post-biotic treatment was 37.0 times, both higher than the NC group and close to the VE-positive control group.

[0082] Example 7: In vitro digestion resistance test of Lactobacillus acidophilus Deepsea100 in simulated gastric and intestinal juices. Humans need to digest food by gastric juice and intestinal juice. A simulated digestive solution was prepared to fully simulate the digestive environment in human gastric juice and intestines, and the tolerance of Lactobacillus acidophilus Deepsea100 was measured.

[0083] (1) Tolerance test to artificial gastric juice Pepsin (p7000) was prepared into a 2 g / L pepsin solution using sterilized 0.85% physiological saline. The pH was adjusted to 3.0 with 4 mol / L hydrochloric acid solution, and then filtered through a 0.22 μm microporous membrane for sterilization before use.

[0084] Add 1 mL of Lactobacillus acidophilus Deepsea100 bacterial suspension to 9 mL of prepared artificial gastric fluid, mix thoroughly, then take 1 mL of the mixture and dilute it tenfold to a certain gradient. After shaking and mixing, take 100 μL and use the pour plate method to determine the viable bacteria count, which is recorded as follows: N 0; Simultaneously, the simulated gastric fluid was incubated at 37°C for 2 hours, and then 1 mL of the mixture was diluted tenfold to a certain gradient. After shaking evenly, 100 μL was taken and the viable bacterial count was determined using the pour plate method, and recorded as 0. N 1. The survival rate of bacterial strains in simulated gastric fluid was calculated according to the formula [6]:

[0085] The survival rate of Lactobacillus acidophilus Deepsea100 in simulated gastric fluid was calculated to be (95.70±0.49)%, indicating that Lactobacillus acidophilus Deepsea100 grew well after entering the gastric fluid environment. The low pH environment in the gastric fluid caused only a very small number of bacteria to die, while the vast majority of bacteria survived. It has a strong tolerance to acid and pepsin and can survive well in the simulated gastric fluid environment.

[0086] (2) Tolerance test for artificial intestinal fluid Prepare a 2 g / L solution of trypsin (USP (P7545)) using sterilized 0.85% physiological saline. Add ox bile salt to control the concentration to 0.2% (m / v). Adjust the pH to 8.0 with 1 mol / L sodium hydroxide. Then filter the solution through a 0.22 μm microporous membrane for sterilization before use.

[0087] The *Lactobacillus acidophilus* Deepsea100 bacterial suspension, after incubation in artificial gastric fluid for 2 hours, was shaken thoroughly. 1 mL of this suspension was added to 9 mL of prepared artificial intestinal fluid, mixed thoroughly, and incubated at 37°C for 1 hour. Then, 1 mL of the mixture was diluted tenfold to a specific gradient, shaken thoroughly, and 100 μL was taken for viable bacterial count using the pour plate method. This result was recorded as follows: N 2. The survival rate of the strain in the simulated intestinal fluid was calculated according to the formula [7]:

[0088] The survival rate of Lactobacillus acidophilus Deepsea100 in simulated artificial intestinal fluid was calculated to be (95.76±0.83)%, indicating that Lactobacillus acidophilus Deepsea100 grew well after entering the intestinal fluid environment. The high bile salt concentration in the intestinal fluid caused a very small number of bacteria to die, while the vast majority of bacteria survived. It has a strong tolerance to bile salts and can survive well in the simulated intestinal fluid environment.

[0089] Example 8: Determination of the intestinal colonization ability of Lactobacillus acidophilus Deepsea100 8.1 Determination of the hydrophobicity of bacterial cells The hydrophobicity of bacterial surfaces is a key factor in their adhesion to the host's intestinal epithelial cells. Strains with strong hydrophobicity are more likely to bind to intestinal epithelial cells through hydrophobic interactions, thereby enhancing their colonization ability. Studies have confirmed a significant positive correlation between bacterial hydrophobicity and intestinal colonization ability.

[0090] After activating the strain for two generations, wash the cells with PBS 2-3 times to adjust the bacterial count to 1.0 × 10⁻⁶. 9cfu / mL, and its absorbance value A0 at 600nm was measured. Take 3mL of bacterial suspension and add it to 1mL of xylene. After pre-culturing at room temperature for 10min, vortex mix quickly for 2min, and then let stand at room temperature for 15min. After the solution is separated into layers, the lower aqueous phase is taken out and its absorbance value A at 600nm is measured. Each sample is replicated in 3 copies. The well-known foreign strain Lactobacillus rhamnosus LGG is used as a positive control. The hydrophobicity of the cell surface of the strain is calculated according to the cell surface hydrophobicity formula [8]:

[0091] The results showed that LGG had a hydrophobicity of 56.42%, which is moderately hydrophobic, while Lactobacillus acidophilus Deepsea100 had a hydrophobicity of 79.86%, which is highly hydrophobic. This indicates that Lactobacillus acidophilus Deepsea100 has a strong ability to colonize the intestines.

[0092] 8.2 Determination of adhesion rate of human colon cancer cells (HT-29) (1) HT-29 cell culture HT-29 cells were cultured in DMEM high-glucose medium supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin and streptotoxin at 37°C, 90% humidity and 5% CO2.

[0093] (2) Adhesion experiment operation steps 1) Liquid culture of experimental strains: Transplanted for 2 generations at an inoculum of 2% (v / v) and incubated statically at 37℃ for 20h~24h; 2) Preparation of monolayers: HT-29 cells were seeded in DMEM medium containing 20% ​​(v / v) fetal bovine serum and cultured. The cells were then transferred to 6-well cell culture plates, and 1 mL of 3×10⁶ cells / well solution was added to each well. 4 Cells at a density of 1 cell / mL were cultured at 37°C with 5% CO2, and the medium was changed every other day until a monolayer was obtained for use. 3) Preparation of bacterial suspension: Take the cultured target strain of bacteria, centrifuge at 10,000 rpm for 1 min at room temperature to collect the bacterial cells, wash twice with sterile PBS, resuspend in DMEM medium, and adjust the bacterial concentration to 1×10⁻⁶. 9 CFU / mL; 4) Co-culture: After preparing a monolayer of HT-29 cells, remove the culture medium, wash twice with PBS buffer, remove the buffer, add 1 mL of the prepared bacterial suspension per well, mix well, and incubate at 37°C for 2 h with 5% CO2. 5) Carefully remove the culture supernatant and rinse 5 times with sterile PBS to remove unadhered bacteria; 6) Add 0.2 mL of trypsin cell digestion solution per well and digest for 5 min to allow the cells to be eluted from the wells of the culture plate. Collect the solution as the sample and perform serial dilution and viable cell count on the collected sample.

[0094] The results showed that the adhesion ability of the positive control LGG to HT-29 cells was (73.69±2.15) CFU / cell, and the adhesion ability of Lactobacillus acidophilus Deepsea100 to HT-29 cells was (98.63±1.78) CFU / cell, indicating that Lactobacillus acidophilus Deepsea100 has good colonization ability on human colonic epithelial cells.

[0095] Example 9 Antibiotic susceptibility assay of Lactobacillus acidophilus Deepsea 100 Lactobacillus acidophilus Deepsea100 was activated for two generations and cultured in MRS liquid culture at 37°C until the turbidity reached 0.5 McFarland. 200 μL of bacterial culture was dropped onto the surface of MRS solid culture medium and evenly spread using a spreader. Within 15 min after inoculation, Liofilchem ​​antimicrobial susceptibility test discs were laid flat on the surface of the culture medium, dried, and then incubated upside down at 37°C for 20-24 h. The diameter of the complete inhibition zone was measured to assess the antibiotic susceptibility of the strain. The results are summarized in Table 8.

[0096] The Liofilchem ​​antibiotic susceptibility testing discs are available in the following specifications: tetracycline (TE, 30 μg / disc), azithromycin (AZM, 15 μg / disc), gentamicin (CN, 10 μg / disc), and vancomycin (VA, 5 μg / disc). According to the interpretation criteria for the inhibition zone of the antibiotic susceptibility testing disc method, tetracycline (TE, 30 μg / disc) with an inhibition zone diameter ≥18 mm is considered sensitive (S); azithromycin (AZM, 15 μg / disc) with an inhibition zone diameter ≥18 mm is considered sensitive (S); and gentamicin (CN, 10 μg / disc) with an inhibition zone diameter of 13 mm to 14 mm is considered neutrally sensitive (S).

[0097] Table 8 Results of antibiotic susceptibility testing of Lactobacillus acidophilus Deepsea100

[0098] From Table 8 and Figure 9 It can be seen that Lactobacillus acidophilus Deepsea100 is sensitive to both tetracycline and azithromycin (S), and neutrally sensitive to gentamicin (S), indicating that Lactobacillus acidophilus Deepsea100 does not have antibiotic resistance and is safe.

[0099] Example 10 Hemolytic activity assay of Lactobacillus acidophilus Deepsea 100 Add 20% sterile defibrinated sheep blood to the MRS+cysteine ​​solid medium preparation solution at 50℃~55℃, mix well, pour into a petri dish, and allow to solidify to obtain blood agar medium; activate Lactobacillus acidophilus Deepsea100 for 2 generations, pick single colonies and streak them on the blood agar medium, and then use Staphylococcus aureus (… Staphylococcus Aureus Use ATCC25923 as a positive control, incubate at 37℃ for 24 hours, and observe whether a hemolytic clear zone appears around the colony. If so, the colony is positive for hemolysis.

[0100] like Figure 10 , 11 As shown, all positive control group Staphylococcus aureus ATCC25923 showed hemolytic zones, while Lactobacillus acidophilus Deepsea100 did not show hemolytic zones. This indicates that the strain does not exhibit hemolysis, does not carry toxins or pathogenic genes that may damage red blood cells, and will not trigger a hemolytic reaction, thus avoiding damage to the host's blood system and making it safe for use in food.

[0101] Example 11 Lactobacillus acidophilus Deepsea100 bacterial agent This invention provides a Lactobacillus acidophilus Deepsea100 inoculum, prepared according to the following steps: Lactobacillus acidophilus Deepsea100 was activated for two generations at an inoculation rate of 3% (v / v), then inoculated into MRS liquid medium and cultured in a constant temperature incubator at 37℃ for 24 h. After that, it was centrifuged at 4℃ and 8000 rpm for 5 min, and the supernatant was removed to retain the bacterial sludge.

[0102] After mixing the bacterial sludge with the freeze-drying protectant at a mass ratio of 1:(1~2), the mixture was encapsulated to obtain encapsulated bacterial sludge. The encapsulated bacterial sludge was stored at -80℃ overnight, and then the pre-frozen encapsulated bacterial sludge was freeze-dried in a vacuum freeze dryer for 48 hours to obtain Lactobacillus acidophilus Deepsea100 freeze-dried bacterial powder with a viable count of 100 billion CFU / g.

[0103] The freeze-drying protectant consists of 8g skim milk powder, 2g sucrose, and 100g distilled water, which are stirred and dissolved, sterilized at 85°C for 30 minutes, and then cooled before use. It should be noted that the freeze-drying protectant can be composed of other protectants or formulations, including but not limited to the above-described embodiments.

[0104] Example 12: Lactobacillus acidophilus Deepsea100 probiotic product This invention provides a Lactobacillus acidophilus Deepsea100 probiotic solid beverage, which is prepared according to the following steps: By weight percentage, 2% of Lactobacillus acidophilus Deepsea100 bacterial powder, 10% of Astragalus membranaceus powder, 10% of Ginseng powder, 10% of Mulberry leaf powder, 10% of Polygonatum sibiricum powder, 8% of Sorbitol, 29% of Maltodextrin, 1% of Xanthan gum, and 20% of Fructooligosaccharides were mixed to obtain a probiotic solid beverage with anti-aging function.

[0105] It should be noted that this embodiment is only an example of the application of Lactobacillus acidophilus Deepsea100 in probiotic solid beverages. Lactobacillus acidophilus Deepsea100 can also be applied to other probiotic solid beverage formulations, including but not limited to the probiotic solid beverage shown in this embodiment. The selection and ratio of ingredients can also be adapted, including but not limited to maltodextrin, fructooligosaccharides, and polygonatum powder in this embodiment.

[0106] The Lactobacillus acidophilus Deepsea100, which has blood sugar-lowering, fat-reducing, and anti-aging functions, provided by this invention, was isolated from the intestinal sample of New Zealand long-lived fish. It is a naturally sourced strain with high food safety. Its fermentation product has a DPPH free radical scavenging rate of ≥96%, a hydroxyl free radical scavenging rate of ≥83%, an α-amylase inhibition rate of ≥71%, an α-glucosidase inhibition rate of ≥65%, and a pancreatic lipase inhibition rate of ≥66%. It is resistant to gastric acid and bile salts and can effectively colonize in the intestine. It can be used in the preparation of food, health products, cosmetics, or animal feed and has significant commercial value.

[0107] The Lactobacillus acidophilus Deepsea100 with blood sugar-lowering, fat-reducing, and anti-aging functions provided by this invention can be used as a raw material component in probiotic products, functional products, and fermented products. Its effects include, but are not limited to, lowering blood sugar, reducing fat, prolonging life, enhancing reproductive capacity, improving heat stress resistance, and enhancing athletic performance. All effects beneficial to the human body are acceptable. The product forms include solid dosage forms such as powders and tablets, or liquid dosage forms suitable for oral administration.

[0108] It should also be noted that although terms such as "functional product" are frequently used herein, the term "product" is used broadly to include human food and drink, and in some embodiments, the product is suitable for and designed for human consumption. The use of these terms is merely for the convenience of describing and explaining the essence of the invention, and does not preclude the possibility of using other terms; interpreting them as any additional limitation would be contrary to the spirit of the invention.

[0109] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A type of Lactobacillus acidophilus ( Lactobacillus acidophilus Deepsea100, characterized by: The accession number is CGMCC No. 36868.

2. A microbial agent, characterized in that: Its components include Lactobacillus acidophilus Deepsea100 as described in claim 1.

3. The microbial agent according to claim 2, characterized in that: The bacterial agent is any one of the following: powder, solution, granules, and capsules of Lactobacillus acidophilus Deepsea100.

4. A probiotic product, characterized in that: Its components include Lactobacillus acidophilus Deepsea100 as described in claim 1.

5. A fermented product, characterized in that: Its components include Lactobacillus acidophilus Deepsea100 as described in claim 1.

6. The fermentation product according to claim 5, characterized in that: The fermentation product is any one of the fermentation broth, bacterial suspension, supernatant, and inactivated fermentation broth of Lactobacillus acidophilus Deepsea100.

7. The fermentation product according to claim 6, characterized in that: The fermentation product has a DPPH radical scavenging rate of ≥96% and / or a hydroxyl radical scavenging rate of ≥83%.

8. The fermentation product according to claim 6, characterized in that: The fermentation product has an inhibition rate of ≥71% against α-amylase, and / or an inhibition rate of ≥65% against α-glucosidase, and / or an inhibition rate of ≥66% against pancreatic lipase.

9. The use of Lactobacillus acidophilus Deepsea100 as described in claim 1 in the preparation of food, health products, cosmetics or animal feed.

10. The application according to claim 9, characterized in that, The food, health product, cosmetic, or animal feed has at least one of the following functions: (1) Extend lifespan; (2) Enhance reproductive capacity; (3) Improve heat stress resistance; (4) Enhance physical activity.

Images